 |
|
Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl–Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease
Forecasting the Incremental Benefits of Preventing Coronary and Cerebrovascular Events
Steven A. Grover, MD, MPA, FRCPC;
Louis Coupal, MSc;
Steeve Paquet, MSc;
Hanna Zowall, MA
Arch Intern Med. 1999;159:593-600.
Objective To forecast the long-term benefits and cost-effectiveness of lipid modification in the secondary prevention of cardiovascular disease.
Methods A validated model based on data from the Lipid Research Clinics cohort was used to estimate the benefits and cost-effectiveness of lipid modification with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) based on results from the Scandinavian Simvastatin Survival Study (4S), including a 35% decrease in low-density-lipoprotein (LDL)–cholesterol levels and an 8% increase in high-density-lipoprotein (HDL)–cholesterol levels. After comparing the short-term outcomes predicted for the 4S with the results actually observed, we forecast the long-term risk of recurrent myocardial infarction, congestive heart failure, transient ischemic attacks, arrhythmias, and strokes and the need for surgical procedures such as coronary artery bypass grafting, catheterization, angioplasty, and pacemaker insertions. Outpatient follow-up care costs were estimated, as were the costs of hospital care and drug therapy. All costs were expressed in 1996 US dollars.
Results The short-term outcomes predicted for the 4S were consistent with the observed results. The long-term benefits of lipid modification among low-risk subjects (normotensive nonsmokers) with a baseline LDL/HDL ratio of 5 but no other risk factors ranged from $5424 to $9548 per year of life saved for men and $8389 to $13,747 per year of life saved for women. In high-risk subjects (hypertensive smokers) with an LDL/HDL ratio of 5, the estimated costs ranged from $4487 to $8532 per year of life saved in men and $5138 to $8389 per year of life saved in women. Assuming that lipid modification has no effect on the risk of stroke, cost-effectiveness increased by as much as 100%.
Conclusions These long-term cost estimates are consistent with the short-term economic analyses of the published 4S results. The long-term treatment of hyperlipidemia in secondary prevention is forecasted to be cost-effective across a broad range of patients between 40 and 70 years of age. Recognizing the additional effects of lipid changes on cerebrovascular events can substantially improve the cost-effectiveness of treating hyperlipidemia.
From the Centre for the Analysis of Cost-Effective Care (Dr Grover, Messrs Coupal and Paquet, and Ms Zowall) and the Divisions of General Internal Medicine and Clinical Epidemiology, The Montreal General Hospital (Dr Grover); and the Departments of Medicine and Epidemiology and Biostatistics, McGill University (Dr Grover), Montreal, Quebec.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention.
Franco et al.
J. Epidemiol. Community Health 2006;60:839-845.
ABSTRACT
| FULL TEXT
Cost effectiveness of statins in coronary heart disease
Franco et al.
J. Epidemiol. Community Health 2005;59:927-933.
ABSTRACT
| FULL TEXT
Treating Osteoarthritis With Cyclooxygenase-2-Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?
Grover et al.
Hypertension 2005;45:92-97.
ABSTRACT
| FULL TEXT
In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization: A Propensity Analysis
Aronow et al.
Arch Intern Med 2003;163:2576-2582.
ABSTRACT
| FULL TEXT
The Importance of Indirect Costs in Primary Cardiovascular Disease Prevention: Can We Save Lives and Money With Statins?
Grover et al.
Arch Intern Med 2003;163:333-339.
ABSTRACT
| FULL TEXT
References
Circulation 2002;106:3373-3421.
FULL TEXT
Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz et al.
J Am Coll Cardiol 2002;40:603-615.
FULL TEXT
Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions
Davidson
J CARDIOVASC PHARMACOL THER 2001;6:219-229.
ABSTRACT
How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?
Grover et al.
Diabetes Care 2001;24:45-50.
ABSTRACT
| FULL TEXT
Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
Grover et al.
CMAJ 2000;163:1263-1269.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?
Grover et al.
Circulation 2000;102:722-727.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
Ganz et al.
ANN INTERN MED 2000;132:780-787.
ABSTRACT
| FULL TEXT
|
